• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    6/20/23 1:38:32 PM ET
    $BCLI
    $BFRI
    $BNOX
    $DICE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCLI alert in real time by email

    Gainers

    • Evelo Biosciences (NASDAQ:EVLO) shares increased by 49.2% to $0.18 during Tuesday's regular session. Trading volume for this security as of 13:37 EST is 108.6 million, which is 1561.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.0 million.
    • DICE Therapeutics (NASDAQ:DICE) shares increased by 37.14% to $46.42. DICE Therapeutics's stock is trading at a volume of 24.7 million shares as of 13:37 EST. This is 5175.1% of its average full-day volume over the last 100 days. The company's market cap stands at $2.2 billion.
    • Owlet (NYSE:OWLT) stock moved upwards by 33.2% to $0.33. Trading volume for Owlet's stock is 27.0 million as of 13:37 EST. This is 4445.2% of its average full-day volume over the last 100 days. The company's market cap stands at $39.1 million.
    • Zura Bio (NASDAQ:ZURA) stock moved upwards by 21.72% to $11.54. Trading volume for Zura Bio's stock is 709.0K as of 13:37 EST. This is 93.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $497.3 million.
    • Summit Therapeutics (NASDAQ:SMMT) shares moved upwards by 20.91% to $2.52. As of 13:37 EST, this security is trading at a volume of 3.6 million shares, making up 207.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.7 billion.
    • Biofrontera (NASDAQ:BFRI) shares moved upwards by 19.77% to $0.53. Biofrontera's stock is trading at a volume of 5.3 million shares as of 13:37 EST. This is 4748.6% of its average full-day volume over the last 100 days. The company's market cap stands at $14.0 million.

    Losers

    • Surgalign Holdings (NASDAQ:SRGA) stock decreased by 77.1% to $0.28 during Tuesday's regular session. Surgalign Holdings's stock is trading at a volume of 5.9 million shares as of 13:37 EST. This is 7104.6% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares decreased by 14.89% to $2.23. As of 13:37 EST, Brainstorm Cell's stock is trading at a volume of 1.0 million, which is 259.2% of its average full-day volume over the last 100 days. The company's market cap stands at $87.8 million.
    • Gracell Biotechnologies (NASDAQ:GRCL) shares decreased by 13.24% to $4.26. Gracell Biotechnologies's stock is trading at a volume of 1.2 million shares as of 13:37 EST. This is 522.5% of its average full-day volume over the last 100 days. The company's market cap stands at $288.4 million.
    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares fell 13.08% to $1.13. The company's market cap stands at $6.1 million.
    • HUTCHMED (China) (NASDAQ:HCM) shares fell 12.66% to $12.15. The current volume of 128.6K shares is 103.2% of HUTCHMED (China)'s average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $2.1 billion.
    • Bionomics (NASDAQ:BNOX) shares decreased by 12.57% to $2.4. The market value of their outstanding shares is at $19.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI
    $BFRI
    $BNOX
    $DICE

    CompanyDatePrice TargetRatingAnalyst
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Owlet Inc.
    $OWLT
    12/9/2025Outperform
    William Blair
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    More analyst ratings

    $BCLI
    $BFRI
    $BNOX
    $DICE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Owlet

    William Blair initiated coverage of Owlet with a rating of Outperform

    12/9/25 8:52:06 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    $BCLI
    $BFRI
    $BNOX
    $DICE
    SEC Filings

    View All

    SEC Form EFFECT filed by Owlet Inc.

    EFFECT - Owlet, Inc. (0001816708) (Filer)

    3/13/26 12:15:14 AM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    3/11/26 6:08:56 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    3/10/26 4:05:03 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BFRI
    $BNOX
    $DICE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Cheng Chig Fung claimed ownership of 1,463,698 units of ordinary shares and claimed ownership of 56,693 units of American depositary shares (SEC Form 3)

    3 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    3/11/26 8:22:08 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Yang Ling

    3 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    3/10/26 9:05:24 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Tan Daniel Shao Weng

    3 - HUTCHMED (China) Ltd (0001648257) (Issuer)

    3/10/26 9:02:43 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BFRI
    $BNOX
    $DICE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

    • Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promising potential future indication for Ameluz®, significantly broadening the Company's dermatology pipeline WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced results of its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid HCL) topical gel, 1

    3/9/26 9:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc. ("Epizyme"), an Ipsen ("Ipsen") company, in China. Epizyme is the Marketing Authorization Holder of TAZVERIK® in the Chinese mainland, for which HUTCHMED Limited (a subsidiary of the Company) acts as the domestic agent/licensee. Ipsen has informed HUTCHMED that it is voluntarily withdrawing TAZVERIK® in the US. As a result, steps have been taken to initiate the market withdrawal and product recall in China. Consequently,

    3/9/26 5:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BFRI
    $BNOX
    $DICE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BFRI
    $BNOX
    $DICE
    Leadership Updates

    Live Leadership Updates

    View All

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCLI
    $BFRI
    $BNOX
    $DICE
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Owlet Reports Fourth Quarter and Full Year 2025 Results; Initiates 2026 Guidance

    Owlet, Inc. ("Owlet" or the "Company") (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the fourth quarter and full year ended December 31, 2025. Owlet's President and Chief Executive Officer, Jonathan Harris, and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company's results and provide a business update today, March 5, 2026, at 4:30 p.m. ET. Q4 2025 Financial Highlights: Q4 Revenue of $26.6 million, up 29.6% from Q4 2024 Q4 Gross Profit of $12.6 million, up $1.7 million from Q4 2024 despite tariff cost impacts; Q4 Gross Margin of 47.6% Q4 Operating Loss of $4.9 million, compared to operating lo

    3/5/26 4:05:00 PM ET
    $OWLT
    Industrial Machinery/Components
    Industrials

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $BFRI
    $BNOX
    $DICE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zura Bio Limited

    SC 13G - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 4:47:14 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care